Jakafi

Generic name: ruxolitinib

Used for: Myelofibrosis (scarring of the bone marrow) · Polycythemia vera (too many red blood cells) · Graft-versus-host disease (GVHD) · 2 more

How do you pay?

How to pay the least

Ask for the cash price

Jakafi

We didn’t find one.

  1. Ask your pharmacy for Jakafi’s cash price, and one or two other pharmacies too.
  2. Jakafi’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameJakafi
Authorized genericruxolitinib
Regular genericruxolitinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Jakafi?
The original
–
–

Brand nameThe maker’s card

IncyteCARES Savings Program for JAKAFI/JAKAFI XR

Savings card from Incyte

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on incytecares.com 

Or call 1-855-452-5234.

In the maker’s words

“If you’d like, we can contact your specialty pharmacy to provide your program information so you can begin receiving JAKAFI or JAKAFI XR for as little as $0 per month right away.”

From the maker’s offer on incytecares.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Jakafi itself, from the same company, sold without the brand name, and usually for less. For now Jakafi is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

JAKAFI/JAKAFI XR is a kinase inhibitor indicated for treatment of:

  • intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults.
  • polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea.
  • steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.
  • chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Source: the FDA label for Jakafi (Incyte Corporation), July 20, 2026. Full label on DailyMed 

Good to know

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/jakafi/